"Centro de Investigaciones Metabólicas, especializados en trastornos cardiometabólicos."

During the past decade, Centro de Investigaciones Metabólicas (CINME) conducted 50 clinical trials. In the 10-year time frame, 50 clinical trials started and 18 clinical trials were completed, i.e. on average, 36% percent of trials that started reached the finish line to date. In the past 5 years, 36 clinical trials started and 18 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Investigaciones Metabólicas (CINME)" #1 sponsor was "Eli Lilly and Company" with 32 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Pfizer" with 4 trials sponsored, "Bayer" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Investigaciones Metabólicas (CINME)" #1 collaborator was "Incyte Corporation" with 4 trials as a collaborator, "Dermira, Inc." with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Investigaciones Metabólicas (CINME)" are "Atopic Dermatitis" (5 trials), "Obesity" (5 trials), "Type 2 Diabetes" (5 trials), "Overweight" (4 trials) and "Alopecia Areata" (3 trials). Many other conditions were trialed in "Centro de Investigaciones Metabólicas (CINME)" in a lesser frequency.

Most popular intervention types in "Centro de Investigaciones Metabólicas (CINME)" are "Drug" (48 trials), "Other" (6 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Tirzepatide" (9 trials), "Baricitinib" (4 trials), "Insulin Degludec" (4 trials) and "Mirikizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Investigaciones Metabólicas (CINME)" are 47 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Centro de Investigaciones Metabólicas (CINME)". undefined are not yet recruiting, 18 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Centro de Investigaciones Metabólicas (CINME), undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Investigaciones Metabólicas (CINME), 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".